Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 5/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 2/20 | 0.31 |
| ▸ | CTSG | P08311 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.30 |
| ▸ | CCND1 | P24385 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12424598 | 0.85 | CNR2 (0.35) | CNR1CNR2PDK2EP300PARP1 | |
| SCHEMBL1531801 | 0.85 | PDK2 (0.36) | CNR1CNR2PDK2EP300PARP1 | |
| SCHEMBL3920058 | 0.82 | PDK2 (0.36) | CNR1CNR2PDK2EP300PARP1 | |
| SCHEMBL1963710 | 0.81 | PDK2 (0.37) | PDK2EP300PARP1GAAHPGD | |
| SCHEMBL12424633 | 0.78 | ESR1 (0.40) | PDK2EP300PARP1GAAHPGD | |
| SCHEMBL28683000 | 0.77 | KCNH2 (0.37) | CNR1CNR2PDK2EP300 | |
| SCHEMBL12424646 | 0.76 | SCN9A (0.33) | HPGD | |
| SCHEMBL26629573 | 0.75 | PDK2 (0.37) | CNR1CNR2PDK2EP300PARP1 | |
| SCHEMBL12424663 | 0.74 | HSP90AA1 (0.31) | — | |
| SCHEMBL1531822 | 0.74 | KMT2A (0.41) | PDK2EP300PARP1CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7976739-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7976739-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20100230649-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100230649-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2055698-A1 | CHROMENE COMPOUND | Tokuyama Corporation (JP) | 2009-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100230649-A1 | CHROMENE COMPOUND | CCNT1, RB1, H1-0 | CNR1 1045/4885CNR2 1581/4885PDK2 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.